A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.
about
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancerIntravesical electromotive drug administration for non-muscle invasive bladder cancerThe role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancerCombination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysisPredictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical TherapyManaging the adverse events of intravesical bacillus Calmette-Guérin therapyTreatment options in non-muscle-invasive bladder cancer after BCG failureApproaching the optimal transurethral resection of a bladder tumorDefining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancerBacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineBladder cancer biomarker discovery using global metabolomic profiling of urineCurrent clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis.Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection.Significance of random bladder biopsies in non-muscle invasive bladder cancer.Bladder cancer and urothelial impairment: the role of TRPV1 as potential drug target.Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report.Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers.Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.CXCL1 is elevated in the urine of bladder cancer patients.Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation.A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuriaCLT1 targets bladder cancer through integrin α5β1 and CLIC3Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomyClinical Practice Pattern of Immediate Intravesical Chemotherapy following Transurethral Resection of a Bladder Tumor in Korea: National Health Insurance Database StudyAre we following the guidelines on non-muscle invasive bladder cancer?Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerNoninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence.Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: time period-related comparison between Japan and Western countriesThe Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder CancerChallenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist.Can neutrophil to lymphocyte ratio predict lamina propria invasion in patients with non muscle invasive bladder cancer?High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.Follow-up procedures for non-muscle-invasive bladder cancer: an update.Current intravesical therapy for non-muscle invasive bladder cancer.Toll-like receptors in urothelial cells--targets for cancer immunotherapy.Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
P2860
Q24186083-431C7B33-B074-491E-9163-FDC373CD9166Q24187574-8E4AF862-70D1-4169-9155-A2A1B18D8A50Q26770422-622FE1F2-491B-4307-B492-2781EF75962EQ26773381-1C1CE678-35CC-4A16-9787-52ECB839245AQ26774965-98757B8B-9D87-4008-9852-945FD243740FQ26775644-8E57DB92-9973-4971-8E89-A1EC5B562152Q26775977-399DF6D5-D22C-4397-830E-B0B56CE08292Q26829828-C4966DB0-70AA-49FF-876A-FC3E7F2F50E6Q26852084-C982631A-0781-4C36-A867-4F9816FDE5ACQ27006765-D93D7D08-6245-4BD0-9285-58211A77239BQ28542873-ADDE70F2-AA60-4EDF-BE51-4F378D684AFEQ30596342-51A50D33-C0F4-4178-A1BD-8D489BF60348Q30930265-3A3B89D1-3E9A-436A-A594-B1AC4BBC3F43Q33578579-CFB3204C-2C7F-4A11-B74E-61168DD2BDE1Q33597571-12DD6338-8483-4A28-A450-8971DCEA933BQ33667193-3777155F-011E-4139-8DA7-28AE8538D4A4Q34370868-8843CB18-1C62-443B-B1AF-ED9E34F201E0Q34788410-977773D8-3612-44B2-9E9A-00D11B558B22Q35050111-298F48D1-3835-4715-8AA4-4F79A7EF9920Q35089307-C48CDA73-C842-4409-8217-0839C3E83BD4Q36234075-E690DA3B-B619-4E40-B0D3-2EF629A5EB4CQ36338886-86D5FC4B-8351-4CF9-8C10-00DA703ED3AFQ36510984-7C8FF230-8185-4692-9371-4C4FD5FAF5B2Q36513100-6E017C95-562D-4143-ADEF-87B25D4DA9D7Q36628548-BDE21DEC-37C0-41D3-932F-8F039161095DQ36654421-2095B577-5096-4273-9CFD-B423F6035989Q36687904-6C3C24CB-0E27-4E2A-B78C-5BEA3105F9B0Q36738114-03E8F1DE-A52A-49C5-AA65-6B3F61882BC2Q37024604-19280AFC-4632-4C04-A6B0-8C2A73D43C17Q37053820-745EF621-F13C-494B-9557-AED26D3BE8C8Q37250675-126011E4-BEE4-4DB2-B14E-8CB868EC5907Q37471721-93978D1A-07C0-47EA-8600-43201848B57FQ37530349-F27DF9A1-40D5-4696-B4CC-1F42DDAB8E6EQ37577902-8777F254-A914-4AEC-AE3D-57A83419215FQ37626500-AA4B4100-AD5E-4477-9755-729BADDCAC9EQ38052445-BA0716FD-428D-4731-B4D8-5AE0254151E3Q38055500-C5E4029D-60B2-4CBE-AFDF-66CE999E3634Q38129947-06C0D04B-9065-43DB-B9D3-BA74D1F94E4EQ38131726-90678EE4-714A-4BFA-A699-45EAABE1F5BBQ38163897-36F00880-3A06-4D1B-B743-D84368E70BB0
P2860
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A review of current guidelines ...... national Bladder Cancer Group.
@en
A review of current guidelines ...... national Bladder Cancer Group.
@nl
type
label
A review of current guidelines ...... national Bladder Cancer Group.
@en
A review of current guidelines ...... national Bladder Cancer Group.
@nl
prefLabel
A review of current guidelines ...... national Bladder Cancer Group.
@en
A review of current guidelines ...... national Bladder Cancer Group.
@nl
P2093
P1476
A review of current guidelines ...... national Bladder Cancer Group.
@en
P2093
Andreas Böhle
Donald Lamm
Hideyuki Akaza
J Alfred Witjes
Joan Palou
Mark Soloway
Maurizio Brausi
Raj Persad
Roger Buckley
P304
P356
10.1016/J.JURO.2011.07.076
P407
P577
2011-10-19T00:00:00Z